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At long last, politicians, public health officials
and the lay public are recognizing that the
correctional health unit, as Bureau of Prisons
Medical Director, Dr. Newton Kendig puts it,
lies "at the nexus of public health." (Full
speech from the National Conference on
Correctional Health Care located on page 4.)
Why are our care decisions public health
decisions? Simply put: corrections is the set-
ting where our nation’s most at-risk persons
access organized health care.
The topic of creating links between public
health and corrections was the focus of two
recent meetings: the HIV/AIDS Behind Bars
Pre-conference, organized by the HIV
Education / Prison Project at the National
Conference on Correctional Health Care on
November 5, 1999, and the Integrating Public
Health and Corrections Collaborations
Conference in Chicago,  October 5-7, 1999.
Both meetings were well attended by correc-
tional health providers, wardens, sheriffs, and
public health officials - more than 100 correc-
tional specialists attended the Ft. Lauderdale
pre-conference, filling the conference room to
capacity. The Chicago meeting featured an
inspirational plenary offering by the Reverend
Jesse Jackson, who reminded the audience
that we are "all under one big tent," thus deci-
sions about health care made inside prison
and jail walls have an impact on the
community at large. 
This article will provide you with the ingredi-
ents successful public health and correctional
collaborations related to HIV care, and sug-
gestions on the types of programs that might
be implemented in correctional settings, as
described by the speakers at both confer-
ences. In the new millennium, the solution to
providing improved correctional health care
while retaining control of the correctional bud-
get may well be to create links between cor-
rectional health care and public health pro-
grams. 
HIV Testing
Public health HIV testing programs exist in
every state. The tests are offered at local
departments of health, local clinics, health
care vans, and substance abuse centers
through funding by departments of health. In
the past, correctional systems have been
able to take advantage of partnerships with
state and city departments of health to per-
form HIV testing in correctional settings; in
some cases, public health workers may be
recruited to perform HIV pre-counseling and
screening at intake. 
Correctional systems should contact their
state departments of health to inquire whether
the DOH is willing to support the cost of HIV
testing at intake, at least in part, or perform
the HIV test at a discounted rate (compared
to commercial laboratories). 
HIV Treatment
In the pre-managed care era, some state
departments of health were responsible for
providing HIV care to jails and prisons. In
some states, this model still exists, while in
others, DOH activities have shifted. 
In Rhode Island for example, the existing
HIV care program was initiated as a RI
State Department of Health project. The
department of health shifted its funding sup-
port from treatment to prevention, as the
Rhode Island Department of Corrections
assumed fiscal responsibilities for the treat-
ment of the incarcerated. At present, the
Rhode Island DOH supports activities associ-
ated with case management of HIV positive
inmates as well as various peer education
and prevention activities within the ACI.
For more information on Rhode Island’s case
management and peer education pro-
grams, contact Lucille Minuto, Assistant
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Public Health/Correctional Partnerships 
at the Millennium
A b o u t  H e p p
HEPP News, a forum for correctional
problem solving, targets correctional
administrators and HIV/AIDS care
providers including physicians, nurses,
outreach workers, and case managers.
Published monthly and distributed by fax,
HEPP News provides up-to-the-moment
information on HIV treatment, efficient
approaches to administering HIV treatment
in the correctional environment, national
and international news related to HIV in
prisons and jails, and changes in correc-
tional care that impact HIV treatment.
Continuing Medical Education credits are
provided by the Brown University Office of
Continuing Medical Education to physi-
cians who accurately respond to the ques-
tions on the last page of the newsletter.  
The editorial board and contributors to
HEPP News include national and regional
correctional professionals, selected on the
basis of their experience with HIV care in
the correctional setting and their familiarity
with current HIV treatment. We encourage
submissions, feedback, and correspon-
dence from our readership.
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Administrator or Paul Loberti, Chief
Administrator, Office of HIV & AIDS at the
Rhode Island Department of Health at
401.222.2320. 
HIV Transitional Case Management
Transitional case management is an impor-
tant component of discharge planning. It
involves visits to correctional facilities by
community-based case managers who
assist inmates with planning for care after
release and provide a support network for
the patient after his or her return to the
community. 
The States Health Resources and Services
Administration, an agency of the Department
of Health and Human Services, administers
the Ryan White CARE (Comprehensive
AIDS Resources Emergency) Act through
its HIV/AIDS Bureau. The CARE Act was
named in honor of Ryan White, a young
Indiana teenager who died from AIDS in
1990. The CARE Act funds primary health
care and support services for low-income,
uninsured and underinsured individuals and
families affected by HIV/AIDS. 
These funds are distributed to states, U.S.
territories and major metropolitan areas;
local planning bodies then determine funding
based upon priorities within the community.
CARE Act funds do not support the provision
of care in correctional facilities (such as that
normally provided by nurses and doctors
working with HIV patients). However, com-
munity based organizations who receive
Ryan White funding have provided transi-
tional case management in correctional
facilities (see Table 1). 
Funds are available for HIV case manage-
ment and discharge planning correctional
institutions through the Special Projects of
National Significance (SPNS) Program,
which supports innovative models of
HIV/AIDS care for medically under-served
and hard-to-reach populations. In 1999,
seven states received funds from SPNS and
the Centers for Disease Control to improve
continuity of HIV care once individuals are
released from correctional facilities. 
For more information on CARE Act pro-
grams, contact your local health department
or Barbara Aranda-Naranjo, PhD, RN,
FAAN, Director of the SPNS Program, at
301.443.9976. (HRSA’s website is www.hrsa.gov/hab).
The most successful discharge planning
programs invite community-based HIV care
providers to come into the jail or prison and
arrange for the patient’s follow up at the
clinic in the community.
HIV Discharge Medications
Traditionally, correctional systems provide a
supply of medications to inmates upon
release. The amount of medications supplied
is usually linked to the expected delay
between release and re-entry into the com-
munity HIV care system, a duration that may
be shortened by providing links to publicly
funded ADAP (AIDS drug assistance pro-
grams) at the time of release. See Table 2
for a listing of ADAP contacts in high HIV
prevalence states (contact HIV/AIDS Bureau
at HRSA at 301.443.6745). 
One option for correctional HIV providers is
to fill out the ADAP paperwork and obtain
ADAP approval prior to release. The inmate
is then given a contact for the ADAP program
at the time of release and medications can
start as soon as he or she selects a pharma-
cy. An additional "bridge" for the inmate who
is to be released on medications is now pro-
vided by Stadtlanders, one of the major
pharmaceutical contractors to correctional
facilities. Stadtlanders has developed a free
program for discharge medications called
"StadtRelease" (contact Kimberly Betty at
800.833.2510 x31458 or visit the Corrections
Health Care Network archives at www.cor-
rections.com/health/healtharchives.html for
more information).
TB and STD Treatment
Public health programs have consistently
been involved in the diagnosis and treatment
of STDs and TB in correctional settings. The
list of correctional systems with access to
DOH assistance for these diseases is too
long to publish in this space, but would serve
as an indicator of DOH willingness to support
programs addressing the diagnosis and
treatment of diseases that are considered a
"public health concern." It may indeed be
possible to build on existing models of
STD/TB collaborations to increase public
health programmatic support of HIV diagno-
sis and management in correctional settings.
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Public Health/Correctional Partnerships at the Millennium
Continued from page 1
Continued on page 6
PROGRAM
HIV Prevention,
Counseling, 
and Testing
HIV/STD/TB
Diagnosis
HIV Peer
Education
HIV Correctional
Officer
Education
HIV Discharge
Planning
HIV Physician
Education
HIV Medication
Table 1. Examples of some successful public health/corrections collaborations*
* Many other examples of such collaborations exist. If you would like to add to this resources list, please call Betsy
Stubblefield at 401.863.2180 or fax to 401.863.1243. This is a work in progress, and will be available on our website:
www.HIVcorrections.org.
EXAMPLE
Great Brook Valley Health Center and the
Massachusetts DOC (MCI Framingham) Provides HIV
case management, prevention education, counseling and
testing. Funded by the Massachusetts DPH through fed-
eral grants and the Ryan White CARE Act.
National Center for HIV, STDs, and Tuberculosis
Prevention (NCHSTP). Limited funds are available from
the CDC for screening patients for STDs, TB and HIV in
correctional settings, usually as part of a research project.
AIDS Counseling and Education (ACE), at Bedford
Hills Correctional Facility, New York, and Counseling
AIDS Resources Education (CARE) at Taconic Medium
Security Prison, New York, promote HIV harm reduction
among incarcerated women through peer education. The
Womens Prison Association oversees both CARE and
ACE. Funding is provided by the Department of Health
AIDS Institute through the Criminal Justice Initiative and
the Womens Prison Initiative, as well as the Ryan White
CARE Act. 
Centerforce, based in San Quentin, CA, is a community-
based organization  that does prevention, transition, visi-
tation, and literacy teaching for HIV infected inmates and
their families. Funded by the CDC/HRSA Correctional
Demonstration Grants.
Correctional Technical Assistance and Training
Project (CTAT), affiliated with Southeast AIDS Training
and Education Center at Emory University, Atlanta, GA,
provides technical assistance to the seven state grantees
of the HRSA/CDC correctional initiative grants. CTAT
also provides training for corrections personnel in GA and
by special contract to other states.
Transition Linkage to the Community (TLC) provides
transitional planning for Connecticut inmates that helps
bridge the gap between correction and HIV services in
the community.
-AIDS Education and Training Centers (AETC) provide
free onsite programs for correctional health care
providers.
-HEPP News is a free monthly fax newsletter that pro-
vides up-to-the-moment information on correctional HIV
health care.
-HIV Insite is a website that provides updated informa-
tion on HIV health care.
-The Hopkins HIV Report is a bimonthly newsletter for
practitioners caring for patients with HIV/AIDS. Their web-
site also provides updated information on HIV care. 
The Illinois AIDS Drug Assistance Program (ADAP)
helps connect qualified jail and prison inmates with the
state ADAP.
CONTACT
Kerry Grennan
508.875.5258 x147
Health Center 
19 Tacoma Street 
Worcester, MA 01605
NCHSTP
404.639.8011 
1600 Clifton Road NE 
Mailstop E07 
Atlanta, GA 30333
ACE
Liz Mastroenni  
914.241.3100 x4360 LM
247 Harris Road
Bedford Hills, NY10507 
CARE
Kim Collica
914.241.3010 x6125
Centerforce
415.456.9980 x116
64 Main Street
San Quentin, CA 94964
Jackie Zalumas
404.727.2927
735 Gatewood Road NE
Atlanta, GA 30322
Sister Carol Duffy
860.527.1866
Visit: www.hrsa.dhhs.gov
Call 401.863.2180,
Fax 401.863.1243 or
Visit: www.HIVcorrections.org
Visit: http://hivinsite.ucsf.edu/
The Hopkins HIV Report
P.O. Box 5252
Baltimore, MD 21224 
http://hopkins-aids.edu
Judy Eihansen at
ADAP
800.825.3518
Senior Advisory Board
Roderic D. Gottula, M.D.
Society for Correctional Physicians
Theodore M. Hammett, Ph.D.
Abt Associates
Ned E. Heltzer, R.Ph., M.S.
Prison Health Services, Inc.
David Thomas, J.D., M.D.
Florida Dept of Corrections
Managers
Dennis Thomas
HIV Education Prison Project
Michelle Gaseau
The Corrections Connection
Layout
Kimberly Backlund-Lewis
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Promotion and Distribution
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Elizabeth Stubblefield
HIV Education Prison Project
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Dear Colleagues,
Corrections and public health agencies have not recognized the potential their partnership could have
to benefit the public. They come from very different cultures; they are both busy caring for the most vis-
ible needs. Public health differs in two ways from the general health care system: it focuses on a com-
munity and emphasizes prevention. Corrections health has focused on individual inmate/patients at
medical call out and emphasized urgent curative care. But corrections is a community, a group of peo-
ple living in close association, and keeping that community healthy is not only more efficient than wait-
ing to treat after illness occurs or becomes severe but also assures that those being released are
healthier than when they return to the general public. It is far easier to find people and prevent and treat
their health problems while incarcerated than after they return to the "free world."
Where partnerships have developed everyone benefits. In 1996 a fourth of all syphilis cases in Chicago
were found in corrections; disease rates for TB and Hepatitis C may be ten times higher in those enter-
ing corrections than in the general population. If the public health goes "where the action is, will cor-
rections health be ready to work with them? In this issue of HEPP News potential partnerships with pub-
lic health are the common thread. Expect to hear more about these partnerships from many voices this
year. Together we can improve the health of the public as a whole. This can be a truly positive contri-
bution from the stand point of the corrections budget.
Also in this month’s HEPP News is an algorithm for stopping prophylaxis for patients on HAART, a spot-
light on a new community based discharge planning program in Massachusetts, and public health
resource and contact lists. After reviewing this issue, readers should be able to identify the appropriate
time to cease prophylaxis, distinguish between the various public health resources and grant opportu-
nities for correctional health care, and select the correct antiviral treatments in accordance with the find-
ings of recent studies. Next month’s issue will focus on treatment updates.
Thank you for your continued support of HEPP News. We look forward to hearing from you!
Sincerely,
Lester Wright, MD
L E T T E R F R O M T H E E D I T O R
New Options for Initial HIV Treatment
Efavirenz and Two NRTIs
Two studies published in the New England
Journal of Medicine in December (Staszewski et
al., and Starr et al., NEJM. Dec. 16 1999;
341(25): 1865-73, 1874-81) extolled the value of
combining Efavirenz (Sustiva) with two NRTIs.
Dr. Nathan Clumeck compared and commented
on the studies in an editorial entitled "Choosing
the best initial therapy for HIV-1 infection" (1925-
26). The study by Staszewski et al. illustrated the
different perspectives given by an "intent to treat
analysis" (in which every discontinuation of treat-
ment was counted as a treatment failure) and an
"as treated analysis" (which provides a better
assessment of antiretroviral potency). In the
intent to treat analysis, efavirenz (EFZ, Sustiva),
lamivudine (3TC, Epivir) and zidovudine(AZT,
ZDV, Retrovir) appeared to be more effective
than the alternative regimen because more
patients "failed" the alternative (indinavir [IDV,
Crixivan], ZDV, 3TC). When the data published in
Staszeweski et al. was viewed from the "as treat-
ed" perspective, according to Dr. Clumeck, the
two regimens appeared to be more or less equiv-
alent. (However, the authors stated that the
Efavirenz containing regimen had superior antivi-
ral potency). Dr. Clumeck reminded his audience
that we’re still awaiting longer term comparisons
of protease inhibitor containing regimens and
regimens containing NNRTIs instead of PIs.
(Editor’s note: Efavirenz is attractive for correc-
tional use because it is "once a day" and requires
fewer pills (three, for the standard 600 mg QHS
dose) than some protease inhibitors. Abacavir is
associated with rash, myalgia in fever in a signif-
icant proportion of patients, and several patients
have died after developing the rash and then
being re-challenged with Abacavir (Escaut-L;
Liotier-JY; Albengres-E; Cheminot-N; Vittecoq-D.
Abacavir rechallenge has to be avoided in case
of hypersensitivity reaction [letter] AIDS.1999 Jul
30; 13(11): 1419-20.)  Discriminating between
Abacavir toxicity and the flu is critical for correc-
tional HIV providers. Correctional HIV providers
using Abacavir may wish to use the Abacavir
rash/fever evaluation protocol developed by Dr.
Rick Altice and published in April HEPP News.
Efavirenz has also been noted to be associated
with CNS effects such as vivid dreams and mood
changes in a significant proportion of patients;
effects that may either positively or negatively
impact on adherence by correctional patients.
Anecdotal reports of recreational Efavirenz use
have arrived at HEPP News from the West
Coast.)
Protease Inhibitors More Effective at
Suppressing HIV-1 in Lymphoid Tissue
When compared to NRTIs alone, protease
inhibitor containing regimens were more effective
in the suppression of HIV-1 replication in lym-
phoid tissues according to a study published by
L. Ruiz et al. AIDS 1999; 13(1): F1-F8. Lymphoid
tissue was obtained from 12 patients, four of
whom were receiving multiple NRTI therapy and
one who was "sub-optimally" dosed with PIs, and
seven patients who had received PI therapy for at
least 6 months prior to biopsy.  Protease inhibitor-
containing regimens appeared to more effective-
ly reverse HIV-induced immunopathological
changes in the lymphoid tissue. Protease
inhibitors have also been associated with loss of
viral fitness. These potential benefits of protease
inhibitor therapy are worth considering when
decisions related to initial or sequential antiretro-
viral treatment is being considered. 
BID Nelfinavir Approved by FDA
Based on information reported in a study con-
ducted by A Peterson, F. Antunes, KN Arasteh,
FD, Gobel, J Gonzalez and others and reported
in Abstract number 205 at the Seventh European
Conference on Clinical Aspects and Treatment of
HIV infection (Lisbon, Portugal, October 23-27,
1999), the FDA recently approved a modification
of Nelfinavir dosing from 750 TID to 1250 BID.
Study AG 1343-542 compared the long-term
antiviral efficacy of bid versus tid dosing of nelfi-
navir in combination with d4t and 3Tc. The study
showed that 1250 mg bid and 750 TID achieved
equivalent efficacy and safety beyond 48 weeks.
This is an important dose modification that will
simplify protease inhibitor-containing regimens in
correctional settings. By comparison, Indinavir
(crixivan) is dosed three times daily at eight hour
intervals. The combination of Ritonavir (Norvir)
and Saquinavir (Fortovase) is an alternative BID
regimen. (Abstract available at http://www.euro-
aids99.com.)
Preview of February HEPP News
Main article: HIV Treatment Update. Editors
Joe Bick and Anne De Groot will summarize and
comment on the current treatment guidelines.
HIV 101: Listing of current HAART Therapy 
regimens.
HEPPigram: Algorithm for restarting HAART
after re-incarceration
Spotlight: 7th Retrovirus Conference (San
Francisco) : Joe Bick, Anne De Groot, and Rick
Altice will bring you the latest update on correc-
tional HIV management.
News Flashes 
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SPECIAL REPORT - The State of Correctional Health Care at the End of the Millennium
From the National Conference on Correctional Health Care, Ft. Lauderdale, Florida, Nov. 1999
HEPP News received permission to reprint Dr. Kendig’s speech from the
NCCHC. The text of the original has been edited to conform to HEPP News
space requirements. The opinions expressed in this speech are those of
the author and do not necessarily represent the opinions of the Federal
Bureau of Prisons or the Department of Justice.
The importance of health care in America’s jails and prisons has never been
greater. Last month, the National Center for Health Statistics reported continued
declines in deaths from heart disease, cancer, and stroke, and dropped AIDS
as a major cause of mortality.1 Despite these achievements, the Census Bureau
recently announced that the number of persons without health insurance
climbed last year to 44 million Americans.2 The lack of health care coverage
remains concentrated among the uneducated, immigrants, and the otherwise
disadvantaged, who have not proportionally benefited from our advances in
health care. Despite our country’s affluence and medical achievements, we
have yet to determine how to deliver health care equitably and cost-effectively
to all Americans. 
In recognition of our problems with health care delivery, the Surgeon General
has issued a list of priorities for the nation:3 (1) develop a more balanced health
system by encouraging universal access to health care including mental health
and healthy starts for every child, (2) maintain a global approach to disease pre-
vention and health promotion, and (3) eliminate racial and ethnic disparities in
health. 
As correctional health care providers we are poised not only to help meet these
priorities, but to play an essential and pivotal role. Correctional health care has
become a critical nexus for public health interventions, since it is where our
nation’s most at-risk persons access organized health care. It has been stated
that corrections is a microcosm of society, but perhaps it should be restated that
society is a macrocosm of corrections, because prisons are not self-contained.
The treatment of inmates directly affects and reflects on society at large. Our
patients increasingly have more of the problems that most significantly affect
our society: violent behavior, substance abuse, mental illness, and infectious
diseases. Our challenge has never been greater. 
Larger Numbers of Inmates, Longer Sentences
Prison populations continue to grow in both State and Federal systems. At year-
end 1998, more than 1.8 million U.S. residents were in either jail or prison.4 Last
year, the Bureau of Prisons added approximately 10,000 inmates to its popula-
tion and anticipates continued growth. 
Not only do we manage more inmates than ever before, our inmates are our
patients for longer periods of time and present with increasingly complex med-
ical problems. A significant proportion of inmate morbidity is related to sub-
stance abuse. Approximately 60-80% of the nation’s correctional population
have used drugs at some point in their lives, twice the estimated drug use of the
total U.S. population.5 Between 1980 and 1994, the average sentence imposed
on drug offenders increased from 47 to 80 months.6,7 As persons with substance
abuse histories spend more time incarcerated, the opportunities to provide drug
treatment are shifting from the community to jails and prisons.   
Although the press recently described jails and prisons as "incubators of infec-
tious disease,"8 in reality, the prevalence of infectious diseases there largely
results from previously infected inmates entering the correctional systems. Jails
and prisons can fuel infectious disease outbreaks, just as hospitals can, by the
sheer concentration of high risk populations; but these same systems have a
proven role in identifying, treating, and controlling communicable diseases.
HIV, STDs, and TB
State prisons in high prevalence areas are key sites for diagnosing new cases
of HIV in persons at risk, who were previously unaware of their infection. This
dramatic two-year decline has been achieved in a population at high risk of
treatment failure due to ongoing substance abuse prior to incarceration. Jail-
based screening for sexually transmitted diseases (STDs) is now recognized by
large city health departments as a proven strategy for curbing syphilis outbreaks
and identifying asymptomatic high risk populations for other STDs.9 The decline
in tuberculosis (TB) incidence in the U.S. is in part the result of TB screening
programs in urban jails and the completion of directly observed therapy in long
term prisons.
Despite our successes in containing communicable diseases. TB epidemics
continue unabated in most parts of the world; and multi-drug resistant TB has
become a global problem.10 Effective TB control programs in jails and prisons
will be essential to our national efforts to further control TB, or approach TB
elimination. 
Hepatitis C
Hepatitis C viral (HCV) infection presents perhaps the most daunting challenge
for correctional providers, because of the marked prevalence of this chronic
infection among inmates. Correctional health care providers must take an
increasing role in establishing treatment standards for HCV, since the responsi-
bility for managing infected persons will be centered in U.S. jails and prisons.
Mental Illness
A recent correctional health publication reported that jails and prisons house
more mentally ill individuals than hospitals and chronic care mental institutions.11
The institutions housing the chronically mentally ill in America are our large
urban jails. The Bureau of Justice Statistics reported that nearly 300,000 men-
tally ill offenders were held in the nation’s state and federal prisons by midyear
1998 and nearly twice as many mentally ill persons were on probation in the
community.12 Identifying and treating inmates with mental illness has important
public health and public safety ramifications, since offenders with mental illness
are more likely to commit a violent offense or be nonadherent to recommended
behavior changes and treatments that may curb disease transmission.
The Team Model
Inmates as patients are more complicated than ever before, challenging our tra-
ditional models of health care delivery. The Bureau of Prison’s Health Services
Division is drafting a new mission statement: "to provide inmates access to
essential quality health care in a cost effective manner." The Bureau of Prisons
is reviewing various methods of primary care delivery for inmates. In one model,
a team approach is used for providing care. Every inmate is assigned to a
health care team. Chronically ill inmates are routinely scheduled for evaluation.
A nurse triage system evaluates inmate complaints and schedules follow-up
appointments. Using this model, only inmates with true emergencies or urgent
health needs are seen on an unscheduled basis. This model is supported by an
inmate co-pay system for certain services and by ready access to certain over-
the-counter medications in the commissary. 
Determining the level of care provided to inmates is as important as ensuring
access to health care. Whether administrators or direct providers, correctional
workers walk a fine line in deciding what level of care to provide. In reality there
is no accepted community standard for health care in the U.S. because estab-
lished health plans differ widely in the services they provide.
BOP Core Values
The Federal Bureau of Prisons is attempting to better define essential care for
inmates and has identified several core values that should underpin the
Bureau’s scope of services, including: treating all inmates equally, "doing no
harm," respecting inmate autonomy in treatment decisions, recognizing the
importance of treatment on inmate function in activities of daily living, cost
effectiveness, protecting public health, and ensuring public safety. The Bureau’s
goal is to provide inmates the highest quality of care, within the defined scope
of services, without compromising core values.
The Bureau’s mission is not only to provide inmates access to essential quality
care, but also to deliver health care cost-effectively. Health care expenditures
will grow dramatically in the next decade, as much as $1 trillion by some
estimates. Cost containment through traditional managed care efforts has
largely been realized. The escalation of health care budgets will increasingly be
driven by the cost of new technologies and drug therapies. 
Continued on page 5
Captain Newton E. Kendig, MD, Medical Director, Federal Bureau of Prisons
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Washington DC, January.
8 Fackelmann, K. (1999). Hepatitis C behind bars, USA Today, October 19.
9 Skolnick, A. A. (1998). Look behind bars for key to control of STDs. JAMA, 279(2), 97-98.
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BOP Review of State Correctional Facility Health Care Budgets
as reported by Dr. Newton Kendig at the Nov. 99 NCCHC.
Dr. Kendig reported the following findings  at the November 1999 NCCHC conference from an independent
survey of State Correctional SystemsI that was funded by the BOP:
Correctional system health budgets increased 9.1%, on average, between FY 1997 and FY 1998, 
This growth rate was comparable to rates of increases of overall correctional budgets. 
Health care represented, on average, 10.6% of correctional budgets, ranging from 5% to nearly 17%. 
Per capita costs ranged from $2.74 per inmate per day to $11.96 per inmate per day with a mean 
per capita of $7.15 per inmate per day.
As compared to the Corrections Yearbook 1998, systems in this survey ranged $3.13 below to 
$5.70 greater than published rates.
Factors that accounted for 60% of the difference between high and low per capita cost states: 
Type of health care staff (lower cost used fewer mid level practitioners, but physician/inmate ratios did 
not differ between high and low cost states).
Contracted employees vs. Correctional employees (lower cost states used more contracted).
Use of capitated contracts (lower cost states used more capitated contracts, or payment in advance 
for specific services or service types).
HIV testing at intake¥ (lower costs states were less likely to HIV test at intake). 
S A V E T H E
D A T E S
The 2000 National Conference on
African-Americans and AIDS
February 24-25, 2000
Renaissance Hotel, Washington DC
Contact the Office of CME at 
Johns Hopkins. University
Call: 410.955.2959 
Fax: 410.955.0807 
E-mail: cmenet@jhmi.edu
Visit: www.med.jhu.edu/cme
HIV Pathogenesis, Antiretrovirals,
and Other Selected Issues in HIV
Disease Management
February 11, Atlanta, GA
February 26, Los Angeles, CA
March 8, Boston, MA
Sponsored by the
International AIDS Society
E-mail: cme@iasusa.org
Visit: www.iasusa.org
The Science and Treatment of HIV:
An Advanced CME Course for
Clinicians
March 25-29, 2000
Snowmass Village, CO
Call: 415.561.6725
Fax: 415.561.6740
Sponsored by the 
International AIDS Society 
National HIV/AIDS Update
Conference
HIV/AIDS at the Crossroads:
Confronting Critical issues
March 14-17, 2000
San Francisco, CA
Call: 514.874.1998
Fax: 514.874.1580
E-mail nauc@total.net
Visit: www.nauc.org.
National Conference on
Pharmaceutical Care to
Underserved Populations
April 3 -4, 2000
Chapel Hill, NC
Call: 919.966.8138
Email: steve_moore@unc.edu
10th Annual Clinical Care 
Options for HIV Symposium
May 4-5, 2000
Scottsdale, AZ
Phone: 888.391.3996
Fax: 508.528.7880
E-mail: registration@mail.
medscape.com
Visit: http://hiv.medscape.com
/symposium2000
Drug Use, HIV and Hepatitis:
Bringing it All Together
May 7-10, 2000
Baltimore, MD
Call 877.565.3693
Fax: 301.565.3710 
Visit: www.chhatt.net/
conference.htm
R E S O U R C E S
National Center for HIV, STD and TB Prevention,
Divisions of HIV/AIDS Prevention
http//www.CDC.gov/nchstp/
CDC National Prevention Information Network
http//www.cdcnpin.org
Ryan White CARE Act Information
http://158.72.83.3/hab/care.html
Substance Abuse and Mental Health Services
Administration
http//www.samhsa.gov
Health Resources and Services Administration
http//www.hrsa.dhhs.gov/hab/
AIDS Education Training Centers
http//www.hrsa.dhhs.gov/hab/C/4web/aetcroster.htm
National Alliance of State and Territorial AIDS
Directors
http//www.nastad.org
The HIV/AIDS Treatment Information Service
http://www.hivatis.org
The Daily HIV Briefing
http://www.aegis.com
The Corrections Connection
http://www.corrections.com
FUNDING AND PUBLIC HEALTH COLLABORATIONS INFORMATION WEBSITES
.
.
.
.
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.
.
.
Key:
FY signifies fiscal year. 
?The survey did not assess or compare the quality of health care delivered by different systems. No determination
was made as to whether high cost states provided better, equivalent, or lesser standards of care to their inmates
when compared to low cost states. 
¥HIV testing at prison entry was probably a proxy for other cost drivers, since the number of inmates with HIV 
infection was not different between high and low cost states. 
I Lamb-Mechanick, D. & Nelson, J. (1999), Prison health care survey: an analysis of factors influencing per 
capita costs. National Institute of Corrections Report, December.
Continued from page 4
The Health Services Division supports models that uti-
lize professional staff the most efficiently, with the
intended result that staff spend the majority of their work
day using their specific skills and training. Health care
delivery has gotten too expensive for us not to maximize
the use of the staffs specific skills. Doctors and mid-
level practitioners need to see patients, nurses need to
do nursing care, triage patients and manage clinics, and
they need the support staff. 
Evidence Based Disease Management
Evidence-based disease management will be increas-
ingly necessary as more health resources are dedicated
toward preventive health care and the treatment of
chronic illnesses. Structuring therapies through drug for-
mularies alone is no longer sufficient. Pharmaceuticals
have become too expensive and treatment options too
varied. Specific strategies based on evidence-based
data must drive how we treat patients and deliver this
care. This treatment approach not only better utilizes
existing resources, but is also the practice of good
medicine. 
The use of telemedicine and the Internet will lessen the
isolation of correctional medicine while furthering public
safety. The challenge will be to use these technologies
strategically to maximize cost efficiency. Interventions
must improve operations at the frontlines, making it eas-
ier, not more difficult for doctors to treat inmates. New
data systems must ensure that collected information
provides outcome measures that improve correctional
medicine at the most fundamental level, patient care.
(For recent BOP survey see box).
Discharge Planning
Gains in health care delivery are pyrrhic victories if cor-
rectional systems do not improve linkages with commu-
nity-based providers. Working with corrections is a
strategic necessity for public health and is tangibly
demonstrated by funding opportunities from the Centers
for Disease Control and Prevention and other govern-
ment and private organizations. Supporting community
linkages for soon-to-be-released inmates is not suffi-
cient in itself; studies must determine what models are
effective. Broader implementation of effective models
will create safer communities and forge support for fund-
ing these programs. 
Role of Correctional Health Care Providers
As we near the next millennium, what doctors and nurs-
es in U.S. jails and prisons do day in and day out has
never been more important to both public safety and
public health. As prison systems manage larger inmate
populations, with increasingly complex histories of vio-
lence, emotional, and medical problems, maintaining
institutional and public safety is paramount. The role of
correctional health care providers in this effort is no
less than essential, yet is frequently under appreciated.
The provision of consistent, quality health care to
inmates means not just healthier inmates, but creates
safer prisons.
The State of Correctional Health Care at the End of the Millennium
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HIV Education Programs
Free educational material and on-site pro-
grams for care providers, patients, and cor-
rectional staff are available through a wide
variety of publicly funded resources:
(1) HIV Education for Providers
AETC: Federally supported AIDS
Education and Training Centers (funded
through the Department of HHS) have
recently shifted their focus to address the
needs of correctional HIV providers
(http://www.hrsd.dhhs.gov).
HHS: Additional free HIV treatment
resources include the HHS guidelines for
the management of HIV, opportunistic
infection, which are published on the web
(http://hivatis.org/trtgdlns.html) and updated
yearly by a national panel of experts. 
(see page 7, HIV 101). 
Publications: The Johns Hopkins HIV
report, HIV Insite (from the University of
California at San Francisco) and the JAMA
HIV website (http://www.hopkins-aids.edu/,
http://hivinsite.ucsf.edu, http://www.ama-
assn.org/special/hiv/hivhome.htm) are
additional free resources that can be
accessed by correctional HIV providers.
HEPP News: This monthly newsletter is
available at no cost to correctional HIV
providers (fax-back form on page 7; web-
site http://www.corrections.org).  HIV
Inside, another quarterly publication, is
available by request from World Health
Communications (see page 8). Both publi-
cations provide Continuing Medical
Education credit (CME) for providers. CEU
for pharmacists and nurses will be avail-
able later this year.
(2) HIV Education for Patients
Ryan White: Fortunately, patient educa-
tion-and specifically education by peers-is
a primary focus for public health funding.
Both federal and local programs are acces-
sible to correctional HIV providers. The
best contact for information would be the
Ryan White Committee (through your local
health department). They will provide a list
of community based organizations that are
willing to come to your facility to facilitate
educational programs for inmates.
Other HIV Education Programs: A num-
ber of model programs such as ACE
(Bedford Hills, NY), Span (Massachusetts),
and Centerforce (San Quentin, California)
successfully met inmate HIV educational
needs. Some of these programs have
recently demonstrated the positive effects
of HIV education on subsequent HIV risk
behavior after release.2
(3) HIV Education for Staff
Correctional security staff are the "third
partner" in correctional HIV care, since
they control the flow of inmates to medlines
and clinics. In a number of states, AETC-
funded programs that have provided edu-
cation to correctional security staff have
been well-received (see Table 1.) Several
pharmaceutical companies are also devel-
oping free programs in recognition of the
important role that correctional officers play
in patient care. 
Summary
Correctional interventions in the area of HIV
care have had a dramatic impact in the last
decade, mainly due to the identification and
treatment of HIV infected individuals who
were unaware of their infection prior to
incarceration.     Correctional settings can
be where persons at risk learn about HIV,
about how to avoid HIV infection and
become informed consumers, learning how
to manage their disease. However,
advances in HIV treatment in correctional
settings have been uneven at best. Poor
correctional HIV management can have an
adverse impact on public health. Spotty
medication delivery, inattentive prescribing
of HIV medications, and failure to provide
adequate prophylaxis can result in the deliv-
ery of inmates who are sicker and more like-
ly to be infected with drug resistant strains of
HIV back to their communities. For an even
more inspirational view of our role as
providers at the nexus of public health, read
Dr. Newton Kendig’s plenary speech, in this
issue of HEPP News on page 4.
State
California
Connecticut
Washington DC
Florida
Georgia
Illinois
Massachusetts
New Jersey
New York
Pennsylvania
Texas
Central Ryan White Contact
(for information on local RW Committees)
California DOH
Office of AIDS CARE Section
916.323.8949
CT DPH
Bureau of Community Health
860.509.7800
Department of Health
202-939-7822
Florida DOH
Bureau of HIV/AIDS
850.245.4335
Georgia DOH- Prevention Services
Branch
STD/HIV Section
David Johnson  404.657.3100
Judy Eihausen at ADAP
800.825.3518
DOH HIV/AIDS Bureau
617.624.5300
NJ DOH AIDS Prevention/Control
609.984.5874
NY State DOH AIDS Institute
518.473.7542
PA DOH HIV/AIDS Programs
717.783.0479
Texas DOH
HIV/STD Services
512.490.2515
ADAP Contact
Michael Montgomery
Office of AIDS ADAP
916.327.6784
Bette Smith
CT Dept Social Services
860.424.5152
Paul Brown
Agency for HIV/AIDS
202-727-2500
Cyndena Hall
DOH HIV/AIDS Program
850.245.4444 x2547
Libby Brown
Dept of Human Services
404.657.3129
Nancy Abraham
DOH AIDS Activities Section
217.524.5983
Mass HIV Drug Assistance
Program
800.228.2714
Ron Weinstein
DOH Division of AIDS
609.984.6328
AIDS Drug Assistance Program
800.542.2437
AIDS Drug Assistance Program
800.922.9384
State AIDS Fact Line:
800.662.6080
Rhonda Lane
Texas DOH
800.255.1090
Table 2. Ryan White/ADAP contact information
References:
1  Pharmaceutical companies have also recognized the importance of public health- corrections linkages and were instrumental in providing support for these two 
conferences: HIV/AIDS Behind Bars at the Florida NCCHC was supported by an unrestricted grant from Glaxo-Wellcome. Public/Health Corrections collaborations 
was supported by an unrestricted grant from Briston-Myers Squibb. Integrating Public Health and Corrections Collaborations was supported by an unrestricted grant 
from Bristol Meyers Squibb, with additional support from the CDC, the City of Chicago Public Health, the Health Resources and Services Administration, the National 
Institute of Justice, Substance Abuse and Mental Health Services Administration, and in kind contribution from the National Commission on Correctional Health Care.
2  Grinstead, O., Zack, B., Faigeles, B. Health Education & Benefits, April 1, 1998; 26(2) 225-238.
3  Mostashari F, Riley E, Selwyn A, Altice F.  J Acquir Immun Def Syndr and Human Retro. Aug 1, 1998; 18(4) 341-8.
4  Hammett, T. M. Prevention and Treatment of HIV/AIDS: An opportunity not yet seized. HEPP News, December 1999; 2(11).
5  Maruschak, L. (1999), HIV in Prisons 1997, Bureau of Justice Statistics Bulletin, U.S. Department of Justice, Washington DC, November 1998.
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Public Health/Correctional Partnerships at the Millennium
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H
IV
1
0
1 Guidelines for stopping Prophylaxis or Maintenance Therapyin patients with HIV Infection who have responded to a HAART Regimen.
Health and Human Services (HHS) guidelines on treating opportunistic infections now suggest that patients taking expensive and
usually poorly tolerated prophylactic therapy to prevent first episode of disease (e.g., azithromycin or clarithromycin for the preven-
tion of MAC) may stop when CD4 levels have stayed above the threshold for starting prophylaxis for three to six months and there
has been sustained suppression of viral load. This months HIV 101 summarizes the new guidelines. It is critically important for cor-
rectional healthcare providers to counsel patients that the new guidelines are only applicable in the presence of a sustained
response to HAART. Should the patient discontinue HAART therapy or exhibit progression on HAART, the need for treatment and
prevention of opportunistic infections should be reassessed.
Adapted from the MMWR report on August 20, 1999 / 48(RR10);1-59, available at 
http://www.cdc.gov/epo/mmwr/preview/mmwrhtml/rr4810a1.htm#tab13 and the Johns Hopkins University website:  www.hopkins-aids.edu/publica-
tions/report/jan00_5.html Copyright ' 1997, 1998, 1999 The Johns Hopkins University on behalf of its Division of Infectious Diseases and AIDS
Service. All rights reserved
Rating system: 
C= Optional.  Evidence for efficacy insufficient to support recommendation for or against, or efficacy may not outweigh adverse consequences.
II = Evidence from at least one well designed, non-randomized trial or other observational studies.
III = Expert opinion.
*If primary prophylaxis, the patient has never had the condition and this treatment prevents primary occurrence.  If maintenance, the patient had
the condition and this treatment prevented secondary recurrence.
**The correctional provider will need to carefully consider whether the patient is expected to retain HAART benefit over the long term before dis-
continuing treatment. For example, one might be wise not to discontinue prophylaxis in patients who are soon to be released.
Pathogen
Pneumocystis (PCP)
Mycobacterium Avium Complex
(MAI, MAC)
Toxoplasma Gondii
Cytomegalocirus 
(maintenance therapy)
Cryptococcosis
Histoplasmosis
Criteria*
If, as a result of HAART, 
the following changes occur
CD4>200 for more than 3-6 months
(CIII) and sustained VL reduction for 3-6
months (CIII)
see comments
no criteria given
CD4>100-150 for more than 3-6
months(CIII)
no criteria given
no criteria given
Comment**
Only for primary Prophylaxis
Only for primary prophylaxis.
Recommendation now supported by
placebo controlled trial.
Not recommended, but implicit in
Pneumocystis guideline.
Primary prophylaxis is not generally
recommended. Other factors should
also be considered (CII)
Not recommended, but probably safe
for patients with CD4>100 for 3-6
months.
Not recommended, but probably safe
for patients with CD4>100 for 3-6
months.
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Spotlight: New Initiatives in the Massachusetts DOC & DOH
Tim Gagnon is HIV Program Coordinator of the Massachusetts County Jails Program and, with his colleagues at the MA DOH, a recent recipient of one of
the $1 million dollar "Correctional Demonstration Project" grants from HRSA/CDC. We elected to interview Mr. Gagnon about his new grant for this Public
Health/Correctional Linkages issue of HEPP News.
HEPPNews: What has been your involvement with HIV in corrections?
Tim Gagnon: I helped to design a system to deal with HIV throughout the
correctional system, which continues to this day. With some financial help
from the sheriffs and the DPH we were able to get the outside communities
involved. We subcontract a lot of the services in the HIV programs to the
community in order to get HIV a little bit more on everybody’s radar. 
The effect has been really astounding. When we started going in there in ’92
I don’t think there were more than 125 HIV infected inmates being treated
annually in the whole county-jail system. Last year we provided services
to all 1,500 men and women who are HIV infected- just in the county jail
systems. 
HN: The funding you just received from HRSA and the CDC was to start new
discharge planning in the county jails?
TG: Let me back up a little. When you’re talking about jails and houses of
correction you’re talking about a very transient, short prison stay for many
more people. On any given day in Massachusetts, there’s about 25,000 peo-
ple that are incarcerated. Roughly half are in the state system and half are
in the county system. The big difference between the state system and the
county system, because of the length of stays, is that any given year, there
may be close to 60,000 admissions to the county jail system, versus a state
system, which usually averages about 3,000 new persons each year. 
Historically, what has happened in the jail and house of corrections popula-
tions is that people aren’t there long enough for their HIV to become prob-
lematic in a clinical sense. Correctional care providers obviously dealt with
the people that they knew about, but most of the work pre-dating the pro-
grams we have now was not sustained nor was it comprehensive. It didn’t
have to be, because people were never there long enough. 
HN: Given that history, you started your new programs?
TG: (Yes). If inmates have some special needs, the case-workers on the
inside will attempt to get those needs addressed. But we don’t have a man-
date or the ability to follow someone into the community after they have left.
That’s where the new money comes in. We’ve done such a tremendous job
upstream - while people are incarcerated, educating, testing, treating, and
case-managing. We’ve created a situation where in Massachusetts in any
given year over the past few years, we’re discharging anywhere between
1,000 and 1,500 prisoners--men and women with HIV--back to the commu-
nity. Once they get back there, even if we are able to develop a fairly com-
prehensive discharge plan for them, you just don’t know what’s going to
happen to people. 
The grant from HRSA and the CDC will fund three initiatives. One is to start
a statewide network of people who will be community based, whose job is to
help transition former prisoners back into their communities. This program,
called the Transition Intervention Project (TIP), is an expansion of a pilot
mental health transition project that the Mass DPH funded starting a year
and a half ago that has a licensed social worker helping prisoners with
adjustment issues. Our staff will work with jails and prisons three months
before someone gets out-regardless of whether the patients are incarcerat-
ed in the county or the state or even in the federal system. We’re going to
connect our staff to the inmates before they hit the streets in Massachusetts.
The second initiative is to establish a Chlamydia screening program at the
Nashua State Jail in Boston. The third initiative involves prevention educa-
tion work in the community correctional centers.
We’re really excited about this.  Even though a person has made great
strides to deal with their addictive behaviors, get involved in some quality HIV
care and have done well while they are incarcerated, there are a lot of prob-
lems once they get out. Often they don’t have transportation and there might
be language barriers to accessing services. Our programs should be really
helpful, and benefit inmates statewide. 
Some of the easier tasks are getting them an appointment for HIV and help-
ing them maintain access to their medications. But quite often the kinds of
services that recently released inmates with HIV need to access do not tra-
ditionally have anything to do with HIV. The other problems they face are the
more complicated social services needs. Studies have shown that the first 6-
8 months on the street are when people are more likely to do something that
will cause them to be re-incarcerated. There are programs that will do this
kind of work (bridging the gap) such as the Fortune Society in New York, and
Span in Boston.
HN: Where are the programs going to take place?
TG: We did some analysis on exit patterns where we collect client-level data
on all our county-jail inmates, who represent the biggest number of prison
inmates. Our research has concluded that 90% of all the HIV infected pris-
oners who are discharged from correctional facilities in Massachusetts go
back to one of 10 communities in the state. 
We then divided the state up into 6 regions. We want community-based
providers from these particular regions to submit proposals to us to do this
work. We’ll have someone from this office that will coordinate this statewide
project the way I coordinate the jail stuff statewide. On the micro-side, there
are HIV coordinators in all of the prison and jails in Massachusetts. When
someone is getting ready to leave, part of the discharge plan is to connect
them with the representative from their region who will talk to the potential
client. That’s where the relationship is born. Then when the person gets out,
they’ll be able to contact this person. In some cases, the person may pick
them up in the jail when he gets out. 
A lot of times we lose people that way. You’ve spent three months working
on a discharge plan that’s contingent on a guy getting a sober bed at a drug
treatment center on June 5, 1999, and for whatever reason, they decide to
release him on May 26. Now this guy has nowhere to go. This happens very
frequently. So we have to have people who are very mobile and very flexible
on the outside who can be reached by being paged or called on the phone.
Part of our budgeting on this program is to put people on the street with lap-
tops and cell phones so that they’re totally mobile. 
HN: Is there going to be a way for you to measure the success of the
program?
TG: We’re working on an evaluation piece for this right now. We’ll obviously
be keeping track of the kinds of services people access. We’ll create some
unique identifiers for clients to keep track of the kinds of services they’ll uti-
lize while they’re in this phase of their careers. We’d like to see that people
are staying engaged; if they have mental health issues that they’re able to
access mental health treatment, if they’re on meds that they stay adherent,
and stay engaged with their medical providers. That’s what we’re looking for
in terms of outcomes. Certainly if all these things are in place, we would
expect that people are less likely to get back into a behavioral pattern that
will result in re-incarceration, but that remains to be seen.
HN: What is the future of funding for these programs?
TG: Our feeling is that there is a well-funded universe and network of social
services in this state. Certainly it exists with regard to HIV services. It is our
hope that at the end of the funding period, which is three years long, that we
will have better defined this universe of services in terms of which ones these
people need to access more than others. At the end of the funding cycle a
lot of the case management pieces that are being funded by this will most
likely be absorbed by the community based agencies that are funded to pro-
vide a lot of these services in the first place. Our goal is to put ourselves out
of business, in a sense.
HN: When does everything begin?
TG: Its happening right now. We’re in the process of putting the RFP togeth-
er and attempting to hire a statewide coordinator. We are negotiating with the
CDC and HRSA some evaluation criteria that we’ll build into this.
I think that from the public health standpoint, this is an opportunity that is not
realized on a national level-not only with HIV but especially with Hepatitis C
and STDs. There’s a real case to make.  If, as a society, we spend a little bit
of money on preventive health care on this population now, we save a lot of
money 5 to 20 years down the road.   I would like to advocate this work for
reasons other than cost effectiveness, but often that is the strongest case we
can make for these interventions.
Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through
February 29, 2000.  The estimated time for completion of this activity is one hour and there is no fee for participation.
True/False:
1. The combination of efavirenz, lamivudine, and 
zidovudine has been found to be more effective 
than indinavir, zidovudine, and lamivudine.
2. Protease inhibitor containing regimens were more 
effective in the suppression of HIV-1 replication in 
lymphoid tissue than NRTIs alone.
3. Efavirenz has been noted to be associated with 
CNS effects that may impact on adherence by 
correctional patients.
4. The Ryan White CARE Act provides which of the 
following?
a) Funds that help support provision of care to 
incarcerated HIV infected patients.
b) Funds for primary health care and support 
services for low-income, uninsured and underinsured 
individuals and families affected by HIV/AIDS.
c) Support for research or models of HIV/AIDS 
care for medically under-served and hard-to-reach 
populations.
d) Assistance with access to HIV medications for 
under-served populations.
5. When can cytomegalovirus maintenance therapy prophylaxis
be stopped?
a) When a patient has maintained a CD4 count of 100 
for more than 3-6 months, during which time he had 
no OI’s.
b) When a patient has maintained a CD4 count of 150 
for 7 months, during which time he had no OI’s.  
c) When a patient has maintained a CD4 count of at 
least 200 for at least 6 months.
6. Experts suggest is it possible to stop PCP primary prophylaxis
given which criteria?
a) CD4>300 for more than 3-6 months
b) CD4>150 for >6-8 months, and sustained VL
reduction for 3-6 months
c) CD4>200 for >3-6 months and sustained VL
reduction for 3-6 months
d) Not recommended, but probably safe with CD4>100 
for 3-6 months
e) Not recommended
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HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
main article 5  4  3  2  1   5  4  3  2  1   
secondary 5  4  3  2  1   5  4  3  2  1   
article
HIV 101 5  4  3  2  1   5  4  3  2  1   
updates 5  4  3  2  1   5  4  3  2  1   
save the date 5  4  3  2  1   5  4  3  2  1   
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
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